
**CHEMICAL COMPOSITION AND MEASURING THE DISTRIBUTION OF
HAEMANTHIDINE BY MALDI-TOF MS IMAGING FROM *Crinum scabrum*
LEAVES**

Jennifer B. Pardo^a, Amanda E. Feu^a, Faviola A. Vigamonte^b and Warley de S. Borges^{a,*},

^aDepartamento de Química, Universidade Federal do Espírito Santo (UFES), 29075-910 Vitória – ES, Brasil

^bDepartamento de Ciências Farmacêuticas, Universidade Federal do Espírito Santo (UFES), 29075-910 Vitória – ES, Brasil

Received: 02/06/2025; accepted: 06/17/2025; published online: 07/21/2025

*e-mail: warley.borges@ufes.br

General remarks

Solvents of analytical grades with purity higher than 99.5% were purchased from Synth (São Paulo, SP, Brazil). The dehydration oven (Ethik Technology, São Paulo, SP, Brazil) was used. Rotavapor model R-3 (BUCHI, Valinhos, SP, Brazil) connected to a V-100 vacuum pump (BUCHI, Valinhos, SP, Brazil) was used. For open-layer chromatography, 5×30 cm and 5×28 cm glass columns packed with silica gel stationary phase (particle size of 0.04-0.063 mm and 25-40 μm) in hexane were used. Nuclear magnetic resonance (NMR) spectra were recovered on a Varian 400 MHz instrument (Palo Alto, USA) using deuterated chloroform (CDCl_3) as solvent and tetramethylsilane (TMS) as the internal standard both from Sigma-Aldrich (St. Louis, MO, USA). The chemical shift (δ) is in ppm and J values in hertz (Hz).





Figure 1S. Comparison of fragmentation spectra obtained by ESI-LTQ-XL-MS/MS and from GNPS for the alkaloid crinamine



Scheme 1S. Proposed fragmentation pathway for crinamine





Figure 2S. Comparison of fragmentation spectra obtained by ESI-LTQ-XL-MS/MS and from GNPS for the alkaloid lycorine



Scheme 2S. Proposed fragmentation pathway for lycorine

Table 1S. ¹H NMR (400 MHz, CDCl₃) spectroscopic data for compound **1/2**, **3** and **4**, compared with literature values

δ ¹ H, <i>J</i> in Hz						
No.	1 / 2	Haemanthidine/ 6- <i>epi</i> - haemanthidine (400 MHz, CDCl ₃) ¹	3	Crinamine (400 MHz, CD ₃ OD) ²	4	Trisphaeridine (400 MHz, CD ₃ OD) ¹
1	6.20-6.25 m	6.28-6.38 m	6.25 bs	6.10 d (10.5)	8.39 d (9.5)	8.86 dd (8.0, 2.0)
2	6.20-6.25 m	6.28-6.38 m	6.25 bs	6.30 dd (10.5, 2.1)	7.66 m	7.97 td (7.6, 1.6)
3	3.91-3.93 m	3.87 m	3.96-4.02 m	3.99 m	7.71 m	8.01 td (7.6, 1.6)
4	—	—	2.04-2.16 m	2.09 m	8.21 d (9.3)	8.17 dd (8.0, 1.6)
4a	2.17-2.24 m / 2.26-2.33 m	2.38 ddd (13.6, 13.6, 4.4) / 2.27 br dd (12.4, 4.8)	2.08 m	—	—	—
4b	2.09-2.12 m / 2.17-2.24 m	2.20 dd (13.6, 4.4) / 2.07 dd (13.6, 4.8)	2.08 m	—	—	—
4a	3.79 dd (12.0, 6.0) / 3.33-3.37 m	3.73 dd (13.6, 4.8) / 3.28-3.36 m	3.22 dd (4.7, 13.3)	obscured signal	—	—
6	—	—	—	—	9.11 s	9.55 s
6a	— / 5.02 s	— / 5.16 s	3.69 d (16.8)	4.34 d (16.5)	—	—
6b	5.62 s / —	5.87 s / —	4.31 d (16.8)	3.81 d (16.5)	—	—
7	6.98 s / 6.82 s	6.95 s / 6.80 s	6.47 s	6.56 s	7.36 s	7.83 s
10	6.75 s / 6.77 s	6.76 s / 6.78 s	6.80 s	6.85 s	7.93 s	8.44 s
11	—	—	3.96-4.02 m	—	—	—

Table 1S. ¹H NMR (400 MHz, CDCl₃) spectroscopic data for compound **1/2**, **3** and **4**, compared with literature values (cont.)

δ ¹ H, <i>J</i> in Hz						
No.	1 / 2	Haemanthidine/ 6- <i>epi</i> - haemanthidine (400 MHz, CDCl ₃) ¹	3	Crinamine (400 MHz, CD ₃ OD) ²	4	Trisphaeridine (400 MHz, CD ₃ OD) ¹
11 endo	3.91-3.93 m	3.96 m	3.96 m	3.33 (t-like)	—	
12 endo	3.33-3.37 m / 4.21 dd (14.4, 6.8)	4.26 dd (14.0, 6.8) / 3.28-3.36 m	3.31-3.42 m	3.25 (t-like)	—	
12 exo	3.03 dd (17.6, 6.4) / 3.33-3.37 m	3.09 dd (14.4, 2.4) / 3.28-3.36 m	3.38 m	—	—	
OCH ₂ O	5.90 d (1.4) / 5.93 d (1.4)	5.91 2d (1.6) / 5.93 2d (1.3)	5.89 d (1.5) / 5.90 d (1.5)	5.80 s	6.19 s	6.42 s
OCH ₃	3.40 s	3.36 s / 3.34 s	3.40 s	3.41 s	—	—




Figure 3S. ^1H NMR spectrum of compound **C1/2** in CDCl_3 (400 MHz)




Figure 4S. ^1H NMR spectrum of compound **C3** in CDCl_3 (400 MHz)




Figure 5S. ^1H NMR spectrum of compound **C4** in CDCl_3 (400 MHz)




Figure 6S. Comparison of mass spectrum of the HCCA matrix and that of the detected ion corresponding to haemanthidine

REFERENCES

1. Bessa, C. D. P. B.; de Andrade, J. P.; de Oliveira, R. S.; Domingos, E.; Santos, H.; Romão, W.; Bastida, J.; Borges, W. S.; *J. Braz. Chem. Soc.* **2017**, 28, 819. [[Crossref](#)]
2. Akinyele, S. T.; Elusiyan, C. A.; Omisore, N. O.; Adewunmi, C. O.; *J. Ethnopharmacol.* **2022**, 296, 115359. [[Crossref](#)]

